American Century Companies Inc. Purchases 13,904 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

American Century Companies Inc. grew its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 10.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,110 shares of the company’s stock after buying an additional 13,904 shares during the period. American Century Companies Inc. owned 0.14% of MaxCyte worth $565,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new position in MaxCyte during the 1st quarter valued at about $28,000. PNC Financial Services Group Inc. bought a new position in shares of MaxCyte during the fourth quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of MaxCyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock valued at $83,000 after purchasing an additional 7,898 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of MaxCyte by 20.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after purchasing an additional 4,320 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of MaxCyte by 22.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after buying an additional 5,927 shares during the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Trading Up 1.1 %

Shares of NASDAQ:MXCT opened at $3.74 on Thursday. The stock has a fifty day simple moving average of $4.16 and a two-hundred day simple moving average of $4.26. MaxCyte, Inc. has a 12-month low of $2.45 and a 12-month high of $5.55. The stock has a market capitalization of $392.04 million, a price-to-earnings ratio of -10.69 and a beta of 1.40.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The firm had revenue of $10.43 million during the quarter, compared to analyst estimates of $8.20 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. As a group, equities research analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current year.

Insider Activity

In related news, EVP Thomas M. Ross sold 15,476 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the transaction, the executive vice president now directly owns 25,000 shares in the company, valued at approximately $113,500. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Stanley C. Erck sold 21,607 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the transaction, the director now directly owns 269,118 shares of the company’s stock, valued at $998,427.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Thomas M. Ross sold 15,476 shares of MaxCyte stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the sale, the executive vice president now owns 25,000 shares of the company’s stock, valued at $113,500. The disclosure for this sale can be found here. Insiders have sold a total of 89,381 shares of company stock worth $361,678 over the last 90 days. 3.00% of the stock is currently owned by insiders.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.